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Microglia, the resident immune cells of the brain, have important roles in brain health.
However, little is known about the regulation and consequences of microglial activation in the
aging human brain. Here we report that the proportion of morphologically activated microglia
(PAM) in postmortem cortical tissue is strongly associated with β-amyloid, tau-related
neuropathology, and the rate of cognitive decline. Effect sizes for PAM measures are sub-
stantial, comparable to that of APOE ε4, the strongest genetic risk factor for Alzheimer’s
disease, and mediation models support an upstream role for microglial activation in Alz-
heimer’s disease via accumulation of tau. Further, we identify a common variant (rs2997325)
inﬂuencing PAM that also affects in vivo microglial activation measured by [11C]-PBR28 PET
in an independent cohort. Thus, our analyses begin to uncover pathways regulating resident
neuroinﬂammation and identify overlaps of PAM’s genetic architecture with those of Alz-
heimer’s disease and several other traits.
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The function of immune cells in the central nervous system(CNS) has recently become a major focus in humangenetics, as these cells have been implicated in suscept-
ibility to neurodegenerative, autoimmune, and psychiatric dis-
eases. Microglia, the brain’s resident immune cells, are thought to
have important roles in both tempering and exacerbating aging-
related neuropathological processes, but their precise role remains
unclear as they are difﬁcult to access in human subjects. Recently,
a molecularly deﬁned subtype of disease-associated microglia has
been proposed to exist in a mouse model of Alzheimer’s disease
(AD)1. However, transcriptomic identities of isolated microglia
are notoriously plastic2 and highly susceptible to a myriad of
experimental confounds3. Regional and temporal heterogeneity of
microglia subpopulations have also been shown in human and
mouse models based on both molecular and morphological
characteristics.
Recent postmortem studies have shown that microglial den-
sities in speciﬁc regions are associated with a syndromic diagnosis
of both early and late-onset AD4, and a recent systematic review
of 113 studies quantifying microglial activation in postmortem
AD brain highlighted the importance of activation vs. abundance
of these cells in disease5. However, low sample sizes, indirect
measures of microglia, and lack of full antemortem and post-
mortem pathological assessments all limit the insights that can be
drawn from the individual component studies and this systematic
review. Here, we leverage two large cohort studies of cognitive
aging that include antemortem longitudinal cognitive assessments
and structured postmortem histopathological evaluations to
characterize a postmortem measure of microglial activation,
directly observed by immunohistochemical staining and light
microscopy. This morphological assessment of microglial acti-
vation stage represents a clear and robust measurement of neu-
roinﬂammation that cannot be captured by a surrogate marker.
We ﬁrst examine how this measure relates to different aging-
related pathologies. We follow this with causal mediation analyses
aimed at placing microglial activation temporally within the
cascade of pathological events leading to AD. Finally, we perform
genome-wide analyses to identify the genomic architecture of
microglial activation and implement a high-resolution polygenic
risk scoring method based on Mendelian randomization
assumptions to demonstrate putatively causal effects of microglial
activation on multiple human diseases and traits. Figure 1 illus-
trates the set of analyses performed in our study.
Results
Active microglia discriminate pathological AD. The character-
istics of ROS/MAP participants with microglial count data are
presented in Table 1. We ﬁrst performed pairwise Spearman
correlations of each individual microglial density measurement
followed by hierarchical clustering (Supplementary Figure 1),
ﬁnding that stage I microglial densities were more similar
between regions, whereas stage II and III microglial densities were
more highly correlated within cortical and subcortical regions
separately.
Following this observation and prior reports of the presence of
morphologically deﬁned active microglia in much smaller
samples of AD brains (n range= 34–106)5, we performed
benchmarking discriminatory analyses for each microglial density
phenotype (see Fig. 2a for illustrative examples of staged
microglia) in two steps. First, Welch t-tests comparing mean
measures of microglial density between individuals with a
postmortem pathological diagnosis of AD vs. non-AD found
that total microglial density as measured in any region was not
discriminative of AD status (0.33 < p < 0.68; Fig. 2b). On the other
hand, stage III microglial density was different between AD and
non-AD subjects, though this was only true in cortical regions
(midfrontal (MF) p= 1.5 × 10−8, Cohen’s d[95%CI]= 0.80
[0.52,1.08]; inferior temporal (IT) p= 6.4 × 10−9, Cohen’s d[95%
CI]= 0.84[0.55,1.12]). Further, a stronger association was
observed with the proportion of stage III microglia density
relative to total microglia (the proportion of active microglia, or
PAM) (MF p= 1.8 × 10−10, Cohen’s d[95%CI]= 0.91[0.63,1.19];
IT p= 1.5 × 10−11, Cohen’s d[95%CI]= 0.99[0.70,1.28]), conﬁrm-
ing that morphologically activated microglia rather than the total
number of microglia is most important for the accumulation of
AD-related pathology in aging6,7. This is consistent with earlier
work in mice demonstrating that microglial activation rather than
proliferation mediates neurodegeneration8.
Second, logistic regression modeling of pathological AD in the
same sample conﬁrmed our t-test results, ﬁnding that models
including PAM outperformed other models with a maximum
AUC of 0.795 for IT and 0.792 for MF (Fig. 2c; pathological
distributions between pathological AD and non-AD subjects are
described in Supplementary Data 9). Notably, the effects of both
cortical PAM measures were independent of and improved model
performance to a greater extent than the major APOE ε4 genetic
risk factor for AD. In the case of IT, the inclusion of PAM
increased model performance over the co-variate only model by
18% (AUC= 0.745 vs. 0.565), whereas including APOE ε4 status
only yielded a 9.6% increase (AUC= 0.661). Bootstrap analyses
reinforced these ﬁndings, with calibrated PAM-inclusive models
showing 21.4% (IT) and 20.4% (MF) increases in model accuracy
vs. the APOE ε4 status-inclusive model’s 11.9%. In full models
containing both APOE ε4 status and PAM, the effect sizes of each
were comparable for a difference in PAM of one interquartile
range (IQR) (MF ORAPOEε4= 6.9[2.73,17.4], ORPAMIQR[95%CI]=
4.8[2.78,8.15]; IT ORAPOEε4[95%CI]= 6.5[2.39,17.64], ORPAMIQR
[95%CI]= 4.2[2.46,7.15]). Importantly, neither APOE ε4 nor
ε2 status were related to either cortical PAM measure, whether
or not co-variates were included (all p > 0.1).
PAM effects on neuropathology and cognitive decline. Having
found robust effects of PAM on pathologically deﬁned AD, and
given the high degree of neuropathological heterogeneity found in
our cohort9,10, we sought to identify whether effects of PAM were
speciﬁc to β-amyloid (Aβ) and tau (the deﬁning pathologic
characteristics of AD) or were also associated with other neuro-
pathological features commonly observed in aged individuals.
Using robust regression across 18 pathologies, we found that
cortical PAM measures were associated to the greatest extent with
total Aβ load and neuritic amyloid plaque count, and, to a lesser
but still signiﬁcant extent, with paired helical ﬁlament (PHF) tau,
neuroﬁbrillary tangles, and diffuse plaques (Fig. 3a). All rela-
tionships were in the positive direction, whereby an increase in
PAM paralleled an increase in pathology. Notably, we found no
signiﬁcant associations of either subcortical PAM with any
pathology, nor did we ﬁnd association of any PAM measure with
pathologies not related to Aβ or tau accumulation (Fig. 3a). Tests
of person-speciﬁc linear trajectories of cognitive decline revealed
signiﬁcant associations of IT PAM with global cognitive decline,
as well as with decline in all ﬁve cognitive sub-domains (Fig. 3b).
MF PAM was also associated with global cognitive decline, and
four of the ﬁve cognitive sub-domains. Similar to our neuro-
pathological ﬁndings, there were no signiﬁcant associations of
subcortical PAM with cognitive decline.
To test whether associations were missed due to a lack of
regional speciﬁcity in pathological measures, we performed post-
hoc analyses of all PAM measures against detailed regional
pathology data (totaling 95 regional measures of amyloid, tau,
Lewy body, and infarct pathology in both cortical and subcortical
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regions). These analyses mirrored the brain-wide results, ﬁnding
exclusively amyloid-related and tau-related associations with
cortical PAM measures; there were no signiﬁcant associations for
either subcortical PAM measure with any regional phenotypic
measure (Supplementary Figure 3).
Mediation modeling of PAM. We next investigated whether
activated microglia might contribute to or be the result of
accumulating AD pathologies. Mediation analyses found no evi-
dence for direct or mediator effects of PAM on cognitive decline
in the presence of PHFtau; rather, these analyses pointed toward
indirect effects of cortical PAM on cognitive decline via PHFtau
(Supplementary Data 2). Both direct and indirect effects of PAM
were found for PHFtau formation, and thus the sum of evidence
across our models suggests a synergistic involvement of PAM and
Aβ load in affecting global cognitive decline via their effects on
PHFtau (Supplementary Figure 4). Put simply, our data suggest
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Fig. 1 Flowchart of analyses performed in this study. ROS Religious Orders Study, MAP Memory and Aging Project, PAM proportion of activated microglia,
AD Alzheimer’s disease, FUMAGWAS functional mapping and annotation of genome-wide association studies, IMAS Indiana Memory and Aging Study,
GTEx Genotype and Tissue Expression Study, BRAINEAC Brain eQTL Almanac, CADD combined annotation-dependent depletion, MSigDB the Molecular
Signature Database. Beta amyloid ﬁgure adapted from Darvesh, Hopkins & Geula (2003) https://www.nature.com/articles/nrn1035#rightslink.
Neuroﬁbrillary tangles ﬁgure adapted from Alzheimer (1911) Ueber eigenartige Krankheitsfaelle des spaeteren Alters (10.1177/0957154×9100200506)
Table 1 Summary statistics of ROSMAP samples included in analysis
Variable MF (n= 225) IT (n= 219) VM (n= 198) PPUT (n= 218)
Sex (F/M) 147/78 141/78 129/69 140/78
APOE ε4 status (−/+) 178/47 175/44 154/44 172/46
PMI (mean hours, s.d.) 8 (6.9) 8 (6.6) 8 (7.1) 8 (6.9)
Age at study entry (mean years, s.d.) 83 (6) 83 (6) 83 (6) 83 (6)
Age at death (mean years, s.d.) 89 (5.8) 89 (5.8) 89 (5.8) 89 (5.8)
Cognitive AD diagnosis, last visit (CN/MCI/AD) 83/64/71 81/61/71 67/58/67 79/61/71
Postmortem AD diagnosis (AD/non-AD) 90/135 86/133 79/119 86/132
AD Alzheimer’s disease, CN cognitively normal, F female, IT inferior temporal cortex, M male, MCI mild cognitive impairment, MF midfrontal cortex, PMI postmortem interval, PPUT posterior putamen
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Fig. 2 Regional distributions of microglial density phenotypes between pathological AD and non-AD. a Representative immunohistochemistry images of
microglial staging in the MAP cohort. Scale bars are 10 µm. b Density plots showing the distributions of all stages of microglia (total count), active microglia
(stage III only), and PAM across four brain regions (nMF= 225, nIT= 219, nPPUT= 198, nVM= 218). P-values are two-sided for Welch t-tests of means
between AD and non-AD. c Receiver operating characteristic (ROC) curves showing model performance for cortical PAM phenotypes in logistic
regression, with pathological AD diagnosis as outcome, and co-variates as speciﬁed. Area under the curve (AUC) values are for non-bootstrapped models.
IT inferior temporal cortex, MF midfrontal cortex, PPUT posterior putamen, VM ventral medial caudate
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the following chain of events: increased PAM → PHFtau accu-
mulation →worsening cognitive decline. This supports and builds
on cross-sectional analyses suggesting that tau correlates best with
microglial activation over the course of AD11.
PAM and the cortical transcriptome and protein measures. To
further explore the molecular substrates of microglial activation,
we accessed whole transcriptome RNA sequencing (RNAseq) and
targeted proteomic data from prefrontal cortex and performed
robust linear regression of each PAM measure against expression
levels of 47 modules of co-expressed genes (n= 478 participants)
and 67 proteins of interest (n= 807). Proteomic analyses found
increases of Aβ peptide to be associated with increased MF (p=
1.0 × 10−6, Huber’s M= 17.2, n= 187) and IT PAM
(p= 2.9 × 10−5, Huber’s M= 15.9, n= 184), providing an inde-
pendent validation of our observed Aβ-PAM associations from
neuropathological assessments (Supplementary Data 3). Levels of
VGF were also associated with MF PAM (p= 5.3 × 10−4, Huber’s
M=−1.8, n= 187), whereby lower protein levels were observed
with higher PAM (Supplementary Figure 5a). RNA module
expression analyses revealed no signiﬁcant PAM-module asso-
ciations after correction, although the pattern of PAM-module
associations differed based on region (Supplementary Figure 5b),
possibly resulting from the regional speciﬁcity of the RNA
sequencing data. Thus, PAM does not appear to have a strong
effect on the cortical transcriptome, consistent with microglia
representing just a small fraction of the total number of cells in
cortical tissue.
Genetic architecture of microglial activation. Given the
imperfect correlation between MF and IT PAM measures
(Spearman ρ= 0.66), we performed two separate genome-wide
association studies (GWAS). All signiﬁcant and suggestive GWAS
results are listed in Table 2 (details in Supplementary Datas 4
and 5). For IT PAM, a single locus on chromosome 1 reached
genome-wide signiﬁcance (rs183093970; linear regression β=
0.154, SE= 0.024, p= 5.47 × 10−10) (Fig. 4a, b). However, while
the 191 kb region encompassed by this lead SNP contains three
independent signals, all three have low minor allele frequency
(MAF) (0.02 >MAF > 0.015). Notably, this association was driven
by only seven individuals in our sample carrying minor alleles
tagging this haplotype and should therefore be considered cau-
tiously. Beyond this genome-wide signiﬁcant locus, 27 additional
independent regions were associated at p < 1 × 10−5, and map-
ping based on position and combined eQTL evidence identiﬁed a
total of 52 candidate genes as possible functional targets of these
variants (Fig. 4c).
For MF PAM, a different locus on chromosome 1 reached
genome-wide signiﬁcance (top SNP: rs2997325T linear regression
β= 0.039, SE= 0.0066, p= 1.88 × 10−8; Fig. 4d, e, g). Beyond this
lead SNP, 11 additional regions surpassed our suggestive
threshold for association, which mapped to a total of 26 genes
(Fig. 4f). In contrast to rs183093970, rs2997325 is a relatively
common variant (MAF= 0.37), lies 8.9 kb 3′ of a long intergenic
non-coding (Linc) RNA (RP11-170N11.1, LINC01361), and
inﬂuences the expression of LINC01361 in multiple tissues with
combined eQTL mapping evidence of p= 5.35 × 10−12 12.
However, LINC01361 is not measured in our cortical RNAseq
data. Q-value analysis revealed no signiﬁcant overlap in genomic
loci implicated by the two PAM GWAS, though many lead SNPs
in the MF GWAS did reach nominal signiﬁcance (p < 0.05) in the
IT GWAS, and vice versa (Supplementary Data 4).
Gene enrichment analyses were performed separately on the
two sets of mapped genes. For the 52 genes from the IT PAM
GWAS, none of the 30 general tissue types analyzed in GTEx
showed Bonferroni signiﬁcant enrichment (Fig. 4j), though in
more ﬁne-grained analyses of 53 tissues, sigmoid colon was
signiﬁcantly enriched for differential expression of this gene set
(Supplementary Figure 6b). Enrichment for functional gene
categories and diseases found over 600 signiﬁcant results,
primarily relating to immunologic signatures (Supplementary
Data 6). For the list of 26 mapped genes from the MF PAM
GWAS, seven of the 30 general tissue types analyzed in GTEx
showed Bonferroni signiﬁcant enrichment (Fig. 4k). In contrast to
0 5 10
Neuritic plaques
Total beta-amyloid
PHF tau
Diffuse plaques
Neurofibrillary tangles
Cerebral amyloid angiopathy
Cerebral infarcts (gross, sub-acute)
Cerebral infarcts (micro, acute)
Arteriosclerosis
Cerebral infarcts (gross, acute)
Cerebral atherosclerosis
TDP-43
Cerebral infarcts (micro, chronic)
Hippocampal sclerosis
Neuronal loss in substantia nigra
PAM region
Inferior temporal cortex
Midfrontal cortex
Posterior putamen
Ventral medial caudate
Cerebral infarcts (micro, sub-acute)
Lewy body pathology
Cerebral infarcts (gross, chronic)
Semantic memory
Global cognition
Perceptual speed
Episodic memory
Perceptual orientation
Working memory
–5.0 –2.5 2.50
–Log10(p-value)*direction of effect–Log10(p-value)*direction of effecta b
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Table 2 Independent loci identiﬁed by cortical PAM GWAS
PAM
region
Ch Lead SNP SNP
position
A1 A2 Freq
(A1)
Beta
(A1)
P-value Genes mapped to locus (combined positional and/or eQTL mapping)
MF 1 rs2997325 83641424 A T 0.629 −0.0389 1.88E
−08
RP11-170N11.1
1 rs157864 165383761 T C 0.1415 0.0443 8.60E
−06
RXRG
1 rs651691 193958320 T C 0.5531 0.0317 6.45E
−06
2 rs12623587 232160554 A C 0.29 −0.0321 6.00E
−06
C2orf72, PSMD1, HTR2B, ARMC9
3 rs78461316 104858434 T C 0.0587 0.0749 2.54E
−07
7 rs141219652 70367062 C T 0.0226 0.1083 8.72E
−06
10 rs61860520 134826645 T C 0.0543 −0.0719 4.02E
−06
TTC40, LINC01166
11 rs138662357 92058950 C A 0.0555 0.074 3.49E
−07
NDUFB11P1, FAT3, PGAM1P9
13 rs9514523 106927120 T C 0.1871 −0.0386 9.20E
−06
13 rs9521336 110023731 C T 0.2146 0.0378 1.96E
−06
MYO16-AS1, LINC00399
14 rs2105997 107209226 T A 0.2276 0.0388 8.46E
−06
IGHV4-39, HOMER2P1, IGHV4-61, IGHV3-64, IGHV3-66, IGHV1-69, IGHV3-72,
IGHV3-73, IGHV3-74
15 rs144705301 67855035 C T 0.0263 0.11 1.74E
−07
AAGAB, RPS24P16, MAP2K5, SKOR1
IT 1 rs56267558 21005316 T G 0.1287 0.0431 6.40E
−06
MUL1, CDA, PINK1, PINK1-AS, DDOST, KIF17
1 rs113285275 70896319 A G 0.2344 −0.0328 3.10E
−06
HHLA3, CTH
1 rs183093970 88454261 G A 0.0147 0.1535 5.47E
−10
1 rs147836155 113501607 T C 0.0129 0.1346 2.46E
−06
SLC16A1, SLC16A1-AS1
2 rs148259393 28713654 G C 0.0204 0.1038 3.30E
−06
PLB1
2 rs141418970 40576095 T G 0.0102 0.1593 4.82E
−07
SLC8A1
2 rs17018138 80154236 G C 0.05 0.0588 7.53E
−06
CTNNA2
2 rs79341575 129133292 C G 0.0551 0.063 2.75E
−06
GPR17
2 rs60200364 160708050 A G 0.0623 0.0555 2.14E
−06
BAZ2B, LY75, LY75-CD302, PLA2R1, ITGB6
2 rs2348117 201598521 T G 0.8893 −0.0414 9.76E
−06
AOX3P, AOX2P, AC007163.3, PPIL3, RNU6-312P
3 rs9289581 139405842 T G 0.37 0.0271 8.32E
−06
NMNAT3
4 rs7656795 22398514 T C 0.8175 −0.037 1.22E
−06
GPR125
4 rs114105899 23027094 G A 0.0158 0.1197 8.10E
−07
RP11-412P11.1
4 rs10011717 86136864 A G 0.3774 −0.0282 6.09E
−06
4 rs77601419 148249054 T C 0.015 0.1168 2.22E
−06
7 rs77033896 115513816 A G 0.0169 0.1262 6.84E
−07
TFEC, CAV1
8 rs17494322 20673550 G A 0.075 0.0535 4.18E
−06
11 rs139629925 76144667 G A 0.0121 0.1347 5.91E
−06
RP11-111M22.2, C11orf30, LRRC32
11 rs2084308 111051351 T A 0.028 0.0967 4.29E
−07
13 rs7328235 41998022 T C 0.9439 −0.0607 6.72E
−06
MTRF1, OR7E36P
13 rs9567982 48605441 G A 0.1375 0.0394 3.08E
−06
LINC00444, LINC00562, SUCLA2, SUCLA2-AS1, NUDT15, MED4, MED4-AS1,
POLR2KP2
13 rs117372720 61819169 T C 0.0149 0.1092 8.97E
−06
13 rs149383020 112585032 A G 0.0341 0.0787 5.09E
−07
14 rs144434563 91361842 G A 0.0135 0.1265 6.79E
−06
RPS6KA5
14 rs137899216 91830706 T C 0.0277 0.0911 3.06E
−06
GPR68, CCDC88C, SMEK1
17 rs112645358 66248531 T C 0.0384 0.069 9.94E
−06
KPNA2, LRRC37A16P, AMZ2, ARSG
18 rs148222222 65675614 T C 0.0169 0.1133 1.47E
−06
RP11-638L3.1
20 rs71336998 5467150 G A 0.018 0.1266 1.17E
−07
LINC00654
Ch chromosome, A1 allele 1 (effect allele), A2 allele 2, eQTL expression quantitative trait loci, Freq allele frequency, IT inferior temporal cortex, MF midfrontal cortex
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functional enrichment analyses for the 52 IT PAM GWAS genes,
a total of only six unique gene sets showed signiﬁcant enrichment
for MF PAM genes (Supplementary Data 6). Importantly, among
the 78 genes mapped between both GWAS, eight encoded
proteins targeted by known drugs (Supplementary Data 8). Of
these, some, such as Acitretin and Eletripan, are relevant to
immunological and neurological illness; they are used in the
treatment of psoriasis and migraine, respectively.
Given the absence of available replication datasets with
postmortem microglial staging and genome-wide genotype data,
we pursued conﬁrmatory analyses of our GWAS results using
another measure of microglial activation: in vivo translocator
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Fig. 4 Genome-wide association studies (GWAS) of PAM with TSPO PET imaging follow-up. aManhattan plot, (b) Q–Q plot, and (c) locus summary chart
for inferior temporal cortex (IT) PAM, and corresponding, (d) Manhattan plot, (e) Q–Q plot, and (f) locus summary chart for midfrontal cortex (MF) PAM
GWAS. Both analyses co-varied for genotype platform, age at death, sex, postmortem interval, APOE ε4 status, and top three EIGENSTRAT principal
components. g Regional association plot highlighting the MF PAM genome-wide signiﬁcant locus surrounding rs2997325 (p= 1.88 × 10−8, n= 225). The
color of each dot represents degree of linkage disequilibrium at that SNP based on 1000 Genomes Phase 3 reference data. The combined annotation-
dependent depletion (CADD) score is plotted below the regional association plot on a scale from 0 to 20, where 20 indicates a variant with highest
predicted deleteriousness. The RegulomeDB score is plotted below the CADD score, and summarizes evidence for effects on regulatory elements of each
plotted SNP (5= transcription factor-binding site or DNAase peak, 6= other motif altered, 7= no evidence). Below the RegulomeDB plot is an eQTL plot
showing –log10(p-values) for association of each plotted SNP with the expression of the mapped gene RP11-170N11.1 (LINC01361). h Strip chart showing the
signiﬁcant relationship between MF PAM (on y-axis as GWAS covariate-only model residuals) and rs2997325 genotype. i Whisker plot showing the
means and standard deviations of [11C]-PBR28 standard uptake value ratio (SUVR) for the left entorhinal cortex in the PET imaging sample from the
Indiana Memory and Aging Study (p= 0.02, r2= 17.1, n= 27), stratiﬁed by rs2997325 genotype. Model co-varied for TSPO rs6971 genotype, APOE
ε4 status, age at study entry, and sex. Tissue enrichment analyses for (j) IT and (k) MF PAM gene sets in 30 general tissue types from GTEx v7 show
Bonferroni signiﬁcant enrichment (two-sided) of only the MF gene set with colon, salivary gland, breast, small intestine, stomach, lung, and blood vessel
tissues. Heat maps showing enrichment for all 53 tissue types in GTEx v7, including uni-directional analyses for up-regulation and down-regulation
speciﬁcally can be found in Supplementary Figure 5
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protein (TSPO) positron emission tomography (PET) imaging
using the [11C]-PBR28 radioligand. Due to the low MAF of
rs183093970, we could only test the genome-wide signiﬁcant
variant from our MF PAM GWAS (rs2997325). In this slightly
younger sample (µage= 71.2 years), we found that rs2997325T
was signiﬁcantly associated with an increase in [11C]-PBR28
binding in the left entorhinal cortex in vivo (p= 0.02, r2= 17.1;
Fig. 4i), consistent with our ﬁnding that the same allele increased
MF PAM (Fig. 4h).
Role of activated microglia across human traits. Having gen-
erated genome-wide proﬁles of genetic risk for both cortical PAM
measures, we used a high-resolution polygenic scoring-based
method to test for overlap in the genomic underpinnings of
microglial activation and AD, which would suggest a causal link
between microglial activation and AD susceptibility. Secondarily,
we tested 28 other brain and immune-related traits with publicly
available GWAS data to more broadly assess the role of microglia
in susceptibility to human disease. For MF PAM (Fig. 5a, b), AD
showed the strongest polygenic association (p= 1.8 × 10−10, r2=
7.3 × 10−4), and ﬁve other traits had optimal evidence for co-
genetic regulation at a corrected threshold, with educational
attainment showing the second strongest effect (p= 1.1 × 10−5,
r2= 6.2 × 10−5). For IT PAM, AD susceptibility (p= 4.9 × 10−13,
r2= 9.4 × 10−4) was also the most strongly associated, and 12
other traits met our signiﬁcance threshold with educational
attainment (p= 8.2 × 10−7, r2= 7.8 × 10−5) also demonstrating
the second strongest effect. These analyses provide evidence that
the genetic predisposition to having activated microglia also
contributes to making an individual more likely to develop AD.
This result therefore goes beyond simply ﬁnding an enrichment
of AD genes that happen to be expressed in microglia: they
provide evidence that genomic propensity for the active microglia
state is causally related to AD risk.
The association with educational attainment is intriguing and
consistent with our understanding that microglia play an
important role in sculpting the developing brain by pruning
synapses13. Likewise, the association of IT PAM with schizo-
phrenia extends the narrative of the involvement of microglia in
this neuropsychiatric disease14. To be thorough, we repeated
these analyses in the reverse direction, asking whether genetic
susceptibility for each of these 29 traits inﬂuences microglial
activation. In these analyses, we found no association for AD,
suggesting that the causal chain of events most likely ﬂows from
genetic risk →microglial activation →AD. We did ﬁnd that
primary sclerosing cholangitis (PSC) risk inﬂuenced both PAM
measures while a few other traits demonstrated single associations
(Fig. 5c, d). The PSC and inﬂammatory bowel disease associations
may represent shared architecture relating to activated myeloid
cells, since microglia and peripheral macrophages (which are
implicated in these two inﬂammatory diseases) share many
molecular functions.
Discussion
Microglial activation is a well-known phenomenon that has been
implicated in a myriad of pathological processes. However, a
majority of studies have been conducted either in small numbers
of human subjects with limited clinicopathologic data or in
murine model systems whose relevance to human disease is
unclear given (1) that they do not recapitulate the events and
conditions observed in the aging human brain and (2) the
emerging understanding of signiﬁcant differences between aging
human and murine microglia15,16. Our study provides several
important insights. First, microglial activation is not a general
feature of the AD brain: we found it to be elevated in cortical but
not in subcortical structures. Further work now needs to be
conducted to sample a wider array of regions in individuals with a
range of pathologic burden and those without pathology so that
we can better understand the extent to which these regional
differences may be related to the nature of the brain region itself
or the extent to which that region is affected by amyloid or tau
pathology in a given individual. Currently, the data are too sparse
to be able to interpret our results beyond simply noting that PAM
in subcortical regions do not appear to relate to the burden of AD
pathology. Second, other common neuropathologies of older age
do not appear to be signiﬁcantly associated with activated
microglia in the regions tested and therefore do not confound
observed associations with Aβ and tau pathologies. Third, our
modeling suggests that microglial activation leads to cognitive
decline indirectly via the accumulation of PHFtau. This histology-
based result is consistent with transcriptome-based ﬁndings we
have recently reported17.
We also describe the previously unmapped genetic landscape
of microglial activation measured in postmortem human brain;
we found no effect of the APOE locus despite reports that APOE
may be a ligand for important microglial receptors such as
TREM218,19. However, a discovery GWAS returned two sig-
niﬁcant results: the uncommon rs183093970 variant, whose role
remains to be validated, and rs2997325, whose role we conﬁrmed
by assessing the related phenotype of in vivo microglial PET
imaging. The effect of the rs2997325T allele in increasing
microglial activation and [11C]-PBR28 binding should be vali-
dated more extensively, but, given its high frequency and strong
effect, it may be a clinically relevant biomarker requiring atten-
tion in the many studies evaluating the utility of other microglia-
targeted ligands in a clinical setting to diagnose or stage neuro-
logical diseases. While little is known about the biology of
LINC01362 that appears to be inﬂuenced by rs2997325, several of
the suggestive loci implicated by our PAM GWAS were found
within or near genes of functional signiﬁcance. For example, the
Lymphocyte antigen 75 gene (LY75), codes for CD205, a den-
dritic cell surface receptor that interacts with MHC class I
molecules20 and plays an important role in T cell function21.
Further investigation of cortical PAM genetic architecture is
warranted to extend our initial set of observations; replication of
associations with both histologic measures of microglial activa-
tion and TSPO imaging in populations at risk of AD are needed
to assess the utility of these measures as biomarkers that may
inform the diagnosis and/or management of aging-related cog-
nitive decline. In addition, in vitro knock-down and DNA editing
experiments, combined with amyloid and tau-sensitive assays,
will be needed to explore the role of these variants in biological
events related to AD.
There are important limitations to consider in our study. First,
while we were able to test for some regional-speciﬁc effects of
PAM on pathology, we did not always have data on pathology in
the exact tissue samples in which microglia were counted.
Therefore, tightly coupled pathology–microglial associations,
such as those known to exist with acute infarction22, may have
been missed. Whether or not microglial activation is a region-
speciﬁc phenomenon in aging is an unresolved question; both
global and focal distributions have been reported in the aging
brain, albeit using different measurements23,24. Reassuringly, a
recent postmortem investigation of microglial activation mea-
sured morphologically in the brains of 11 late onset AD subjects
vs. 12 age-matched controls also found increases in microglial
activation in cortical but not sub-cortical regions4. Second, we
have a limited sample size for genome-wide analyses, although it
was sufﬁcient to discover the rs2997325 variant which has a
strong effect on both microglial activation and in vivo microglial
imaging. Third, our moderate sample size also means that we
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cannot exclude the possibility that activated microglia may have
weak, undetected effects on non-AD pathologies. Finally, we
acknowledge that our chosen methodologies for quantifying
microglia have intrinsic biases and limitations. For example, the
manual identiﬁcation of stained microglia carries a degree of
subjectivity and, while [11C]-PBR28 is a well-validated biomarker
of microglial activation in humans, experimental confounds and
the potential for non-speciﬁc binding are important to consider
in any molecular imaging experiment. Further, we recognize that
inﬁltrating macrophages present in brain tissue samples may
represent a source of error in our counts since they are largely
indistinguishable from microglia once they are activated.
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Fig. 5 Results of polygenic scoring analysis of PAM GWAS and 29 published traits. a Stratiﬁed violin plots for PAM→ published trait polygenic analyses,
showing –log10(p-values) for genetic score (GRS) associations of inferior temporal cortex (IT) PAM and midfrontal cortex (MF) PAM across all p-value
thresholds ranging from 0 to 0.5, with 5.0 × 10−5 regular increments (10,000 total scores). Each PAM genetic score was mapped onto the summary
statistics of each published GWAS trait and tested for signiﬁcance. The dotted line represents a corrected statistical signiﬁcance threshold of
p= 8.6 × 10−4, corrected for 29 GWAS traits and two PAM measures. The width of each violin represents the density of PAM polygenic scores associated
with each trait at a given signiﬁcance. For example, a bottom-skewed violin (e.g. educational attainment (Edu)) indicates that a majority of scores across
the tested set of thresholds tended to achieve greater signiﬁcance, whereas a top-skewed violin (e.g. bipolar disorder (BPD)) indicates that a majority of
tested scores tended toward lower signiﬁcance. Peaks achieving at least one score above corrected statistical signiﬁcance are labeled for their respective
GWAS trait. b Network plot illustrating signiﬁcant results for PAM→GWAS trait analyses, where an arrow indicates a directional effect of a peak PAM
GRS on a GWAS trait at corrected signiﬁcance (edges are labeled with % variance explained in GWAS trait by optimal PAM GRS, and edge thickness is
proportional to the –log(p-value) of the association). c Stratiﬁed violin plots for the GWAS trait→ PAM analyses, such that GRS were ﬁrst calculated across
thresholds for published traits and then tested against the PAM summary statistics. d Network plot illustrating signiﬁcant results of the GWAS trait→
PAM analyses. GRS genetic risk score, AD Alzheimer’s disease, Edu educational attainment, IBDCD irritable bowel disease, Crohn’s disease; IBDUC
irritable bowel disease, ulcerative colitis, CAD coronary artery disease, HIPP hippocampal volume (from MRI), RA rheumatoid arthritis, BPD bipolar
disorder, MDD major depressive disorder, HOMA homeostasis model assessment (from fasting insulin and glucose); AtopDerm atopic dermatitis, APOB
circulating apolipoprotein B, HDL high-density lipoprotein cholesterol, BMDneck bone marrow density of the neck, SCZ schizophrenia, ADHD attention
deﬁcit/hyperactivity disorder. The full list of abbreviations found in the legend and descriptions of each published GWAS, including sample sizes, are listed
in Supplementary Data 7
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Reassuringly, recent single-cell analyses performed by our group
have shown that these cells represent a negligible minority (~1%)
of myeloid lineage cells present in brain tissue from similar
subjects25. These same single-cell sequencing experiments will be
important for identifying molecular subpopulations of microglia
that may correspond to those activation states captured by the
PAM phenotype.
Despite these limitations, our polygenic analyses revealed sig-
niﬁcant links that clarify and expand the roles of activated
microglia in human diseases. This is clearest for AD where we
reﬁne the narrative of the involvement of myeloid cells in AD
susceptibility by showing that the proportion of activated
microglia has a causal role in AD. A similar result for cognitive
attainment is intriguing as it may be capturing microglia’s role in
synaptic pruning during development and memory consolidation;
however, this is confounded by the fact that this enrichment may
also be capturing the role of microglia in age-related cognitive
decline that we describe in this report. The enrichment for
Crohn’s disease is unlikely to represent a causal role of microglia
in this disease; rather, this result captures the likely overlap of
genetic architecture between activated microglia and other acti-
vated myeloid cells in the periphery that are known to be involved
in Crohn’s disease.
The relevance of recent reports of pathologically important
subtypes of microglia in murine model systems, such as disease-
associated microglia (DAM)1 and dark microglia26, remains to be
demonstrated in the aging human brain since mouse and human
microglia diverge signiﬁcantly in functional molecular signatures
with age27. By studying activated microglia in the target organ in
humans, we have found several key insights, including (1) the
observation that they may accelerate cognitive decline through an
effect on PHFtau accumulation, which enables us to design
mechanistic studies, (2) the discovery and validation of a chro-
mosome 1 locus (among several other suggestive plausible loci)
that provides a biological foundation for dissecting the mechan-
isms of microglial activation, and (3) the effect of rs2997325 on
[11C]-PBR28 binding which may need to be accounted for in
human imaging studies of in vivo microglial activation. Thus,
microglial activation is a central component of AD susceptibility,
and we have begun to elaborate its place in the causal chain of
events leading to increased accumulation of tau pathology and
subsequent cognitive decline, as well as regulatory mechanisms
that inﬂuence this activation.
Methods
Study subjects. All antemortem cognitive and postmortem data analyzed in this
study were gathered as part of the Religious Orders Study and Memory and Aging
Project (ROS/MAP)28–30, two longitudinal cohort studies of the elderly, one from
across the United States and the other from the greater Chicago area. All subjects
were recruited free of dementia (mean age at entry= 78 ± 8.7 (SD) years), agreed to
annual clinical and neurocognitive evaluation, and signed an Anatomical Gift Act
allowing for brain autopsy at time of death. In vivo [11C]-PBR28 PET imaging
acquisitions were collected on data from the Indiana Memory and Aging Study
(IMAS), an ongoing neuroimaging and biomarker study based at the Indiana
University School of Medicine including elderly subjects at multiple levels of
cognitive impairment31. Written informed consent was obtained from all ROS/
MAP and IMAS participants. Study protocols were approved by each site’s Insti-
tutional Review Board. Full methods can be found in Supplementary Methods.
Genomics. Genotype array data for 2067 ROS/MAP subjects were imputed using
the Michigan Imputation Server (Haplotype Reference Consortium reference v1.1).
For IMAS, data were imputed using IMPUTE v2.2 (1000 Genomes phase 1
reference). APOE (rs429358 and rs7412) genotyping was carried out separately
using standard protocols.
Tanscriptomics. RNA sequencing of postmortem dorsolateral prefrontal cortical
tissue from 538 ROS/MAP subjects were available for analysis at the time of study.
Following sequencing and standard quality control32, The Speakeasy algorithm33
was used to cluster expressed genes into functionally cohesive gene modules, which
have been extensively validated for robustness and pathophysiological rele-
vance16,34. Average values of gene expression for each of 47 modules were used as
quantitative outcomes.
Proteomics. Selected reaction monitoring-based (SRM) quantitative proteomics
was used to measure the abundance of 67 proteins (Supplementary Data 3) in
frozen dorsolateral prefrontal cortical tissue from 807 ROS/MAP participants
according to a standard protocol35,36.
Postmortem neuropathology. A total of 18 disease-related and age-related neu-
ropathologies were measured brain-wide (n= 985). Pathologies included multiple
validated measures of Aβ peptides, neuritic and diffuse plaques, hyperpho-
sphorylated tau protein, neuroﬁbrillary tangles, micro and macro cerebral infarcts,
cerebral atherosclerosis, TDP43 proteinopathy, and hippocampal sclerosis, among
others (see Supplementary Methods)37. A subset of up to 225 brain samples were
also evaluated for the presence of microglia at three stages of activation in four
regions (midfrontal (MF) cortex, inferior temporal (IT) cortex, ventral medial
caudate (VM), and posterior putamen (PPUT)), based on morphology: stage I (thin
ramiﬁed processes), stage II (plump cytoplasm and thicker processes), and stage III
(appearance of macrophages).
Antemortem cognitive decline. A total of 1932 subjects with genomic data also
had longitudinal cognitive performance data available at the time of study (the full
list of cognitive tests can be found in Supplementary Data 10).
In vivo TSPO PET imaging. Scans of in vivo [11C]-PBR28 binding were assessed in
27 subjects (nCN= 13, nMCI= 7, nAD= 7) as part of the IMAS study31.
Statistical analysis. Regression analyses were performed in R (v3.3.3)38. PAM was
calculated by the following formula:
PAMr ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S3r
S1r þ S2r þ S3r
s
ð1Þ
where r represents each of four regions and S1, S2, and S3 represent microglial
densities measured in region r at stage I, II, and III, respectively. To address
potential concerns related to PAM distributions and model ﬁtting, we performed
extensive model validation and sensitivity analyses (Supplementary Methods;
Supplementary Figure 2; Supplementary Data 1). Differences in model perfor-
mance are reported as change in C-index, expressed as a percent, which corre-
sponds to the area under the receiver operating characteristics curve (ΔAUC).
Iterative re-weighted least-squares robust regression was used and model validation
was performed using the .632+ bootstrap method39. Models were corrected using
the Bonferroni procedure. Causal mediation modeling for identifying direct and
indirect effects of PAM on cognitive decline was performed using the ‘mediation’ R
package.
GWAS were performed in PLINK40 (v1.90) using imputed genotype dosages
and additive linear models, co-varying for age at death, postmortem interval (PMI),
sex, genotype batch, and the ﬁrst three EIGENSTRAT41 principal components.
Signiﬁcance thresholds of p < 2.5 × 10−8 and p < 1.0 × 10−5 (two-sided) were
deemed genome-wide signiﬁcant and suggestive, respectfully. Post-processing of
GWAS results was conducted using the full complement of state-of-the-art tools
available through the recently released Functional Mapping and Annotation of
Genome-Wide Association Studies platform (FUMAGWAS; http://fuma.ctglab.nl/)
42. Analyses included positional and eQTL-based gene mapping, assessment of
Combined Annotation Dependent Depletion (CADD v1.3)43 and RegulomeDB
scores44, tissue expression speciﬁcity using GTEx v7, comprehensive gene set
enrichment analyses, and mapping of gene targets to the DrugBank database45.
Statistical Parametric Mapping version 8 (SPM8) was used for imaging analysis.
Freesurfer (v5.1) was used to deﬁne subject-speciﬁc regions of interest and average
standardized uptake value ratios (SUVRs) were extracted for three bilateral ROIs.
As six ROI values were strongly correlated and the sample size is moderate for
genetic analysis of this type (n= 27), we carried out a multivariate analysis by
performing genetic association analysis using six phenotypes simultaneously to
minimize the number of test performed and increase the statistical power. We used
the software for correlated phenotype analysis (SCOPA) program46 to perform a
single omnibus genetic test for all correlated phenotypes, modeling rs2997325
genotype additively.
To assess causal relationships between the genetic determinants of cortical PAM
(based on our PAM GWAS results) and 29 brain and immune-related traits (and
vice versa), we used a genetic risk score-based method47 as implemented in the
PRSice48 program (v1.25). The full list of traits and published GWAS references are
listed in Supplementary Data 7. Bonferroni correction was applied for 29 traits in
both directions, resulting in a signiﬁcance threshold of p < 8.6 × 10−4.
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Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Access to ROS/MAP data used in the preparation of this manuscript can be applied
for at the Rush Alzheimer’s Disease Center Resource Sharing Hub and is stored on
Synapse Accelerating Medicines Partnership—Alzheimer’s Disease (AMP-AD)
Knowledge Portal (https://www.synapse.org/#!Synapse:syn3219045) [10.7303/
syn3219045]. A reporting summary for this Article is available as a Supplementary
Information File.
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